The pooled HR was 0.83 (95% CI: 0.69–0.99, p = 0.04), with no observed heterogeneity (I2 = 0%) and a narrow prediction interval (0.65–1.04), supporting the generalizability of the effect across patients with diabetes, Figure 8B. These findings suggest that SGLT2 inhibitors may reduce the risk of recurrent MI in patients with T2DM following ACS, with greater consistency and certainty than in the overall population. Here, SLC5A2 is linked to diabetes mellitus.